SG184550A1 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations - Google Patents

Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations Download PDF

Info

Publication number
SG184550A1
SG184550A1 SG2012075511A SG2012075511A SG184550A1 SG 184550 A1 SG184550 A1 SG 184550A1 SG 2012075511 A SG2012075511 A SG 2012075511A SG 2012075511 A SG2012075511 A SG 2012075511A SG 184550 A1 SG184550 A1 SG 184550A1
Authority
SG
Singapore
Prior art keywords
amino
alkyl
phenyl
fluoro
difluoro
Prior art date
Application number
SG2012075511A
Other languages
English (en)
Inventor
Ningshu Liu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG184550(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of SG184550A1 publication Critical patent/SG184550A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG2012075511A 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations SG184550A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (1)

Publication Number Publication Date
SG184550A1 true SG184550A1 (en) 2012-11-29

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012075511A SG184550A1 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Country Status (24)

Country Link
US (1) US20130184270A1 (enExample)
EP (1) EP2558126A2 (enExample)
JP (1) JP5886271B2 (enExample)
KR (1) KR20130098155A (enExample)
CN (1) CN102958540B (enExample)
AU (1) AU2011240003A1 (enExample)
BR (1) BR112012026480A2 (enExample)
CA (1) CA2796253A1 (enExample)
CL (1) CL2012002887A1 (enExample)
CO (1) CO6620036A2 (enExample)
CR (1) CR20120524A (enExample)
CU (1) CU20120150A7 (enExample)
DO (1) DOP2012000269A (enExample)
EA (1) EA201201414A8 (enExample)
EC (1) ECSP12012261A (enExample)
IL (1) IL222356A0 (enExample)
MA (1) MA34158B1 (enExample)
MX (1) MX2012012064A (enExample)
PE (1) PE20130191A1 (enExample)
PH (1) PH12012502069A1 (enExample)
SG (1) SG184550A1 (enExample)
TN (1) TN2012000493A1 (enExample)
WO (1) WO2011128407A2 (enExample)
ZA (1) ZA201208616B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
US9999623B2 (en) 2013-04-08 2018-06-19 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
EA201791974A1 (ru) * 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
CA2978807A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP3426657B1 (en) * 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
PT2042504E (pt) * 2002-09-30 2011-09-07 Bayer Schering Pharma Ag Derivados da azolepirimidina fundida
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004064002B4 (de) 2004-08-04 2019-05-09 Continental Automotive Gmbh System zum Überwachen einer Sensorvorrichtung
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2006272837B2 (en) * 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
BRPI0911297A2 (pt) * 2008-04-14 2019-09-24 Ardea Biosciences Inc composição e métodos para preparo e uso das mesmas
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
ZA201208616B (en) 2015-08-26
CU20120150A7 (es) 2013-02-26
EA201201414A8 (ru) 2013-12-30
TN2012000493A1 (en) 2014-04-01
CN102958540A (zh) 2013-03-06
WO2011128407A2 (en) 2011-10-20
WO2011128407A9 (en) 2011-12-22
BR112012026480A2 (pt) 2016-08-16
IL222356A0 (en) 2012-12-31
PH12012502069A1 (en) 2013-02-04
EP2558126A2 (en) 2013-02-20
CL2012002887A1 (es) 2013-01-18
MA34158B1 (fr) 2013-04-03
MX2012012064A (es) 2012-12-17
AU2011240003A1 (en) 2012-11-08
JP2013525293A (ja) 2013-06-20
WO2011128407A3 (en) 2012-02-23
CA2796253A1 (en) 2011-10-20
CN102958540B (zh) 2015-09-02
PE20130191A1 (es) 2013-02-21
CR20120524A (es) 2013-01-09
JP5886271B2 (ja) 2016-03-16
HK1182937A1 (en) 2013-12-13
DOP2012000269A (es) 2012-12-15
EA201201414A1 (ru) 2013-04-30
CO6620036A2 (es) 2013-02-15
US20130184270A1 (en) 2013-07-18
KR20130098155A (ko) 2013-09-04
ECSP12012261A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
US9381177B2 (en) Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
SG184550A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
AU2012238891B2 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
US9555022B2 (en) Substituted triazolopyridines
CA2517361A1 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
SG188417A1 (en) Substituted imidazopyridazines
WO2014020043A1 (en) Combinations for the treatment of cancer
US8138336B2 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
HK1182937B (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
HK1187811A (en) Substituted n-(2-arylamino)aryl sulfonamide-containing combinations